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OBJECTIVE — To estimate the prevalence of postpartum glucose testing within 6 months of
pregnancies complicated by gestational diabetes mellitus (GDM), assess factors associated
with testing and timing of testing after delivery, and report the test results among tested
women.
RESEARCH DESIGN AND METHODS — This was a retrospective study of 11,825
women who were identiﬁed as having GDM using the 100-g oral glucose tolerance test (OGTT)
from1999to2006.Postpartumtesting(75-g2-hOGTTorfastingplasmaglucose[FPG])within
6 months of delivery and test results from laboratory databases are reported. Postpartum test
results are categorized as normal, impaired fasting glucose (IFG) and/or impaired glucose toler-
ance (IGT), and provisionally diabetic.
RESULTS — About half (n  5,939) the women were tested with either a FPG or 75-g OGTT
from7daysto6monthspostpartum.Ofthesewomen,46%weretestedduringthe6-to12-week
postpartum period. Odds of testing were independently associated with age, race/ethnicity,
household income, education, foreign-born status, parity, mode of delivery, having a postpar-
tumvisit,havingGDMcodedatdischarge,andpharmacotherapyforGDM.Ofthe5,857women
with test results, 16.3% (n  956) had IFG/IGT and 1.1% (n  66) had provisional diabetes.
After adjustment for demographic and clinical factors, abnormal postpartum test results was
associated with having required insulin, glyburide, or metformin during pregnancy and with
longer period from delivery to postpartum testing.
CONCLUSIONS — After a pregnancy complicated by GDM, automated orders for postpar-
tum testing with notiﬁcation to physicians and electronically generated telephone and e-mail
reminder messages to patients may improve the rates of postpartum testing for persistence of
glucose intolerance.
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G
estational diabetes mellitus (GDM)
is deﬁned as any degree of glucose
intolerance with onset or ﬁrst rec-
ognition during pregnancy (1). GDM
complicates 4–14% of pregnancies in the
U.S. annually, with the prevalence vary-
ingsigniﬁcantlywiththedemographicsof
the population studied, as well as differ-
ences in the study methods (2–6).
WomenwithGDMareatincreasedriskof
GDM recurrence (7). Furthermore, the
risk of type 2 diabetes after GDM ranges
from 2 to 70% depending on the popula-
tion being studied and the length of
follow-up (8).
The American Diabetes Association
(ADA) (9) and the American College of
Obstetricians and Gynecologists (ACOG)
(10,11) recommend that women with
GDM be tested for glucose intolerance
from 6 to 12 weeks postpartum. Timely
detection of impaired fasting glucose
(IFG) and impaired glucose tolerance
(IGT)mayprovideanopportunitytopre-
vent or delay the onset of type 2 diabetes
through diet, physical activity, weight
management, and/or pharmacological in-
tervention. However, only a fraction of
women who have GDM are tested during
the postpartum period (12–17).
To assess the prevalence of postpar-
tum glucose testing among women with a
recent history of GDM, we examined the
proportion of women who had glucose
testing in the postpartum period and
the demographic, clinical, and health
system–related factors that were associ-
ated with being tested, as well as the tim-
ing of postpartum testing, in a racially/
ethnically diverse sample of women from
a managed health care organization. Ad-
ditionally, we reported the prevalence of
women tested who had impaired glucose
regulation (IFG and/or IGT and a provi-
sional diagnosis of diabetes) and the de-
mographic and clinical characteristics of
these women that were associated with
having these results.
RESEARCH DESIGN AND
METHODS
Population and data sources
The Kaiser Permanente Southern Califor-
nia (KPSC) Medical Care Program is a
large prepaid group-practice managed
health care organization with over 3.2
million members. Members receive their
health care in KPSC-owned facilities
throughouttheseven-countyregion.This
study was approved by the KPSC institu-
tional review board. The study popula-
tion consisted of women who had one or
more singleton births at 20 weeks ges-
tation in KPSC hospitals, who were iden-
tiﬁedashavingGDMusingthe100-goral
glucosetolerancetest(OGTT)from1Jan-
uary 1999 through 31 December 2006,
and who remained KPSC members for at
least 6 months postpartum. One ran-
domly selected pregnancy was included
in the analyses for women who had had
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duringthestudyperiod.Ofthewomenin
the ﬁnal sample, 3% had more than one
GDM-affected pregnancy during the
study period.
Identiﬁcation of women with GDM
An algorithm using outpatient encounter
and inpatient hospitalization codes, labo-
ratory test results, and pharmacy pre-
scription records was applied to identify
women with evidence of diabetes before
pregnancy (2,18). After excluding these
women, we used the results from the
100-g 3-h OGTT to identify women who
had had GDM based on at least two ab-
normal plasma glucose measurements
greaterthanorequaltotheCarpenterand
Coustan threshold values recommended
by the ADA (fasting 95 mg/dl, 1-h 180
mg/dl, 2-h 155 mg/dl, 3-h 140 mg/dl)
(19).
Postpartum glucose testing
Women who had a 2-h 75-g OGTT or
fasting plasma glucose (FPG) alone in the
period from 7 days to 6 months postpar-
tum were considered “tested,” while
womenwithouttestingorthosewithonly
a random (nonfasting) plasma glucose
during this period were considered “not
tested” for the purposes of this study.
Time to ﬁrst OGTT or FPG after delivery
was calculated by determining the num-
ber of days from the infant birth date to
the ﬁrst testing date. We further catego-
rized tested women based on timing of
their ﬁrst test as 7 days postpartum up to
6 weeks postpartum (“early” testing win-
dow), 6–12 weeks postpartum (“ADA-
recommended” testing window) (9,10),
and after 12 weeks through 6 months
postpartum (“late” testing window).
Categorization of postpartum
glucose testing results
Using the ADA criteria, we deﬁned
women with an FPG (whether alone or as
part of a 75-g OGTT) 100 mg/dl as nor-
mal, 100–125 mg/dl as IFG, and 126
mg/dl as having a provisional diagnosis of
diabetes (1). Categories based on the glu-
cose concentration 2 h after a 75-g post-
glucoseloadwereasfollows:140mg/dl
normal, 140–199 mg/dl IGT, and 200
mg/dl provisionally diabetic. Women
with IFG and/or IGT (IFG/IGT) were
combined into one category. For women
with more than one test during the
follow-up period during separate visits,
the outcome is reported based on the
most abnormal test result.
Other measures
Information derived from the infants’
birth certiﬁcates that were included in
these analyses included maternal age,
race/ethnicity (categorized as Hispanic
[regardless of race], white, black, Asian,
or Paciﬁc Islander [Asian/PI] and all “oth-
ers”), country of birth (U.S. or foreign
born),infantbirthweight,andgestational
age at delivery. Median household in-
come was based on the estimated median
household income in the census block
group in which the woman resided. Phar-
macotherapy for GDM was deﬁned as
having one or more prescriptions ﬁlled
for oral hyperglycemia agents (metformin
or glyburide) and/or insulin at a KPSC
pharmacy during pregnancy. GDM was
considered noted in the medical record if
the International Classiﬁcation of Diseases
(ICD) code 648.8 was included among
the discharge diagnoses after delivery.
The postpartum visit was deﬁned as a
clinical visit with a physician, certiﬁed
nurse midwife, or nurse practitioner in
theobstetricsandgynecologydepartment
from 6–12 weeks postpartum.
Statistical analysis
We estimated the prevalence of postpar-
tum glucose testing by dividing the num-
ber of women with postpartum glucose
testing giving birth that year by the total
number of women with GDM pregnan-
cies giving birth during that year. We ex-
amined the associations between
demographic, clinical, and health care–
related characteristics and postpartum
glucose testing (yes/no) and time to ﬁrst
postpartum glucose test after delivery (7
days to 6 weeks, 6–12 weeks, 12
weeks to 6 months). Associations be-
tween categorical variables and postpar-
tum outcomes were assessed using 
2
tests. Multiple logistic regression models
were used to calculate the adjusted odds
ratio (OR) and corresponding 95% CIs to
assess the associations between demo-
graphic, clinical, and health care–related
characteristics and postpartum glucose
testing.
Among women with a postpartum
glucose test, we examined the associa-
tions between these characteristics and
postpartum test results (normal, IFG/
IGT, or diabetes). We also explored the
mean fasting, 1-h, 2-h, and 3-h values
from the 100-g 3-h OGTT during preg-
nancy and postpartum glucose testing
(yes/no), timing of postpartum testing,
and outcomes of postpartum testing. Dif-
ferences were evaluated using the Stu-
dent’s t tests and one-way ANOVA in
conjunction with Tukey’s honestly signif-
icant difference to account for multiple
comparisons.
The associations between the post-
partum test result (normal, IFG/IGT, dia-
betes) and the timing of postpartum
testing and pharmacological GDM treat-
ment, respectively, were examined using
multinomial logistic regression to adjust
for maternal demographic characteristics
as well as year of delivery. Women with
normal postpartum glucose values served
as the reference group. Age was treated as
a linear ordinal variable in 5-year incre-
ments. ORs and 95% CIs are reported.
Analyses were performed with SAS ver-
sion 9.1 (SAS Institute, Cary, NC).
RESULTS
Postpartum glucose testing
Of the 11,825 women with a GDM-
affected pregnancy during the 8-year
study period, just over half (50.2%; n 
5,939) had at least one FPG or 75-g
OGTT during the 6-month postpartum
period (Table 1). Of the tested women,
2,458(41.4%)wereﬁrsttestedduringthe
early window, 2,749 (46.3%) during the
ADA recommended 6- to 12-week win-
dow, and 732 (12.3%) during the late
window (Table 1); 79.1% were tested
with FPG only, 18.2% were assessed with
a 75-g OGTT, and 2.7% were given both
tests. Approximately 7% (n  408) of
these women were tested more than once
in the 6 months postpartum, although re-
peated testing was not found to be con-
tingent upon the results of the ﬁrst test
(data not shown).
In the unadjusted analyses, demo-
graphic, clinical, health care characteris-
tics, and year of delivery were all
signiﬁcantly associated with testing (Ta-
ble 1). Timing of the ﬁrst postpartum test
was signiﬁcantly associated with all de-
mographic variables except age and in-
come tertile, all clinical variables except
parity, and year of delivery. In the multi-
ple logistic regression model (Table 1),
odds of testing increased with increasing
maternal age, education, and income and
were higher for foreign-born women
compared with U.S.-born women. The
odds of testing decreased with increasing
parity and were lower for women who
were black or white compared with His-
panic women, for women with cesarean
deliveries, and for women with babies
weighing 4,000 g. Women who were
treated with insulin ( oral agents) had
Postpartum glucose testing after GDM
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who did not receive pharmacotherapy,
whereas women treated with oral agents
alonewerelesslikelytobetested.Finally,
women who did not have GDM coded at
discharge had 39% lower odds of being
tested than those who were so coded. In
contrast, the odds of postpartum testing
were over three times greater for women
whohadapostpartumvisitthanforthose
who had not.
Women who had blood glucose test-
ing postpartum had slightly lower mean
fasting (91.4 vs. 92.8 mg/dl, P  0.0001)
and 3-h values (124.9 vs. 126.6 mg/dl,
P  0.001) on their 100-g OGTT per-
formed during pregnancy than women
who were not tested postpartum (supple-
mentary Fig. 1, available in an online ap-
pendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-2095/DC1). The
mean fasting glucose on the 100-g OGTT
during pregnancy was similar for women
testedduringtheearlypostpartumperiod
andthosetestedduringthe6-to12-week
period (90.9 and 90.8 mg/dl, respec-
tively), whereas women tested in the late
window had a higher mean fasting value
during pregnancy (95.1 mg/dl, P 
0.0001) (supplementary Fig. 2).
Postpartum test results
Of the women tested for whom results
were available (n  5,857; 99%), 16.3%
(n  956) were classiﬁed as IFG/IGT and
1.1% (n  66) as having diabetes. Of the
1,154 women who were given a 2-h 75-g
OGTTpostpartum,810(70.2%)hadnor-
mal fasting and postchallenge values, 172
(14.9%)IFGonly,75(6.5%)IGTonly,71
(6.2%) both IFG and IGT (for a total of
318 women [27.6%] with IFG and/or
IGT), and 26 (2.3%) were found to have
diabetes based on the fasting and/or 2-h
values. Of the 1,065 women who were
given a 2-h 75-g OGTT postpartum with-
out a prior FPG test, 8.1% of 835 women
with a normal FPG had an abnormal 2-h
value (IGT  7.9%, diabetes  0.2%),
and 16.7% of 921 women with normal
2-h values had an abnormal FPG (IFG 
16.5%, diabetes  0.2%). Of the women
who had an FPG only, 12.8% had IFG
and 0.8% were found to have diabetes.
In the unadjusted analyses, demo-
graphic characteristics signiﬁcantly asso-
ciated with test result categories included
all except country of birth (Table 2).
OGTT values observed during pregnancy
all differed signiﬁcantly (P  0.001) be-
tween the three postpartum glucose cate-
gories (supplementary Fig. 3). Both
Table2—Demographic,clinical,andhealthcare–relatedcharacteristicsassociatedwithpost-
partum glucose test results among 5,857 women* who had GDM and who had postpartum
glucose testing, 1999–2006
Normal‡ IFG/IGT‡
Presumptive
diabetes‡
Unadjusted
P†
n 4,835 956 66
Demographics
Age category (years) 0.0402
13–19 37 (78.7) 9 (19.2) 1 (2.1)
20–24 283 (80.8) 64 (18.3) 3 (0.9)
25–29 1,127 (84.3) 197 (14.7) 13 (1.0)
30–34 1,682 (84.0) 294 (14.7) 27 (1.3)
35–39 1,307 (80.9) 292 (18.1) 16 (1.0)
40 399 (79.0) 100 (19.8) 6 (1.2)
Race/ethnicity 0.0074
Hispanic 2,522 (81.4) 535 (17.3) 43 (1.4)
Black 176 (80.4) 39 (17.8) 4 (1.8)
Asian/Paciﬁc Islander 1,078 (82.4) 218 (16.7) 12 (0.9)
Non-Hispanic white 1,004 (86.1) 156 (13.4) 6 (0.5)
Other 55 (85.9) 8 (12.5) 1 (1.6)
Highest education 0.0033
High school 674 (79.1) 167 (19.6) 11 (1.3)
High school graduate 1,256 (81.1) 268 (17.3) 24 (1.6)
High school graduate 2,728 (84.3) 478 (14.8) 29 (0.9)
Unknown 177 (79.7) 43 (19.4) 2 (0.9)
Median household income 0.0002
Lowest 1,403 (80.5) 308 (17.7) 32 (1.8)
Middle 1,589 (81.4) 343 (17.6) 19 (1.0)
Highest 1,789 (85.3) 293 (14.0) 14 (0.7)
Unknown 54 (80.6) 12 (17.9) 1 (1.5)
Country of birth 0.6564
U.S. 1,963 (83.5) 365 (15.5) 24 (1.0)
Outside U.S. 2,722 (81.9) 561 (16.9) 40 (1.2)
Unknown 150 (82.4) 30 (16.5) 2 (1.1)
Clinical
Parity 0.0065
0 1,849 (84.3) 324 (14.8) 19 (0.9)
1 1,523 (82.9) 291 (15.8) 23 (1.3)
2 1,463 (80.0) 341 (18.7) 24 (1.3)
Pharmacological GDM treatment 0.0001
None 3,923 (88.0) 527 (11.8) 9 (0.2)
Insulin (/ oral agents) 789 (64.4) 385 (31.4) 51 (4.2)
Oral agents only 123 (71.1) 44 (25.4) 6 (3.5)
Infant birth weight 0.0001
2,500 g 287 (77.6) 78 (21.1) 5 (1.3)
2,500–3,999 g 4,075 (83.5) 756 (15.5) 47 (1.0)
4,000 g 473 (77.7) 122 (20.0) 14 (2.3)
Health care
Timing of glucose testing 0.0001
7 days to 6 weeks 2,207 (85.0) 373 (6.4) 16 (0.6)
6–12 weeks 2,258 (82.8) 443 (16.2) 27 (1.0)
12 weeks to 6 months 370 (69.4) 140 (26.3) 23 (4.3)
Year 0.0001
1999 331 (72.6) 120 (25.3) 5 (1.1)
2000 542 (79.9) 128 (18.9) 8 (1.2)
2001 655 (82.3) 133 (16.7) 8 (1.0)
2002 734 (85.8) 110 (12.9) 11 (1.3)
2003 698 (86.5) 100 (12.4) 9 (1.1)
2004 637 (83.4) 121 (15.8) 6 (0.8)
2005 635 (82.5) 128 (16.6) 7 (0.9)
2006 603 (82.5) 116 (15.9) 12 (1.6)
*Excludes82womenwhoweretestedbutforwhomtestresultswerenotavailable.†Pvalueisforthe
2test
for each variable separately for the three categories; Monte Carlo simulations for exact P values were used
when any cell size was 10. ‡All percentages are shown as row percentages for outcome distribution within
each covariate strata.
Lawrence and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 573pharmacotherapy and time to postpar-
tum test were highly associated with ab-
normal outcomes in the multinomial
logistic regression analysis (Table 3).
Women treated with insulin during preg-
nancy had 57% higher odds of IFG/IGT
andwereoverthreetimesaslikelytohave
diabetesaswomenwhodidnottakemed-
ication for GDM. Women who took oral
agents only had 40% higher odds of hav-
ing IFG/IGT and were over two times as
likely to have diabetes. In addition,
womentestedbefore6weekspostpartum
were 26% less likely to have IFG/IGT and
58% less likely to have diabetes than
women tested between 6 and 12 weeks
postpartum. In contrast, women who
were tested from 12 weeks to 6 months
postpartumwere55%morelikelytohave
IFG/IGT and over three times as likely to
have diabetes as were women tested from
6 to 12 weeks postpartum. The associa-
tions between postpartum testing period
and GDM treatment and the test result
categories remained highly signiﬁcant,
even after adjustment for the prenatal
OGTT fasting values (data not shown)—
the only prenatal value that differed by
testing period (supplementary Fig. 2).
CONCLUSIONS— Among the mem-
bership of a large managed health care
plan with a high prevalence of GDM, ap-
proximatelyone-halfofwomenidentiﬁed
as having GDM had postpartum glucose
testinginthe6monthsafterdelivery.The
majority of women (79%) tested in the 6
months postpartum had an FPG only.
Only one-half of women who had post-
partum glucose testing had their tests
during the 6- to 12-week postpartum pe-
riod recommended by the ADA. Postpar-
tum testing and timing of testing were
associated with demographic, clinical,
and health care–related factors. Women
whose treatment included insulin alone
or insulin plus oral hypoglycemic agents
had the same odds of being tested post-
partum as those whose treatment did not
include any pharmacologic agents. How-
ever, individuals treated with oral agents
alone had lower odds for being tested
thanthosewhodidnotreceivepharmaco-
therapy during pregnancy.
Of the women tested, a relatively
small proportion (1%) met the criteria
for diabetes, while a greater proportion
(16%) had IFG and/or IGT. However,
detection of IFG/IGT or diabetes was in-
dependently and positively associated
with having been treated with insulin or
oral agents during pregnancy and timing
of postpartum glucose testing. While
women tested between 12 weeks and 6
months postpartum had higher mean
FPG during pregnancy compared with
those tested in the early and ADA-
recommended windows, the association
between being tested in the later period
and having abnormal results postpartum
persisted after controlling for the prenatal
FPG value.
The observation that women not
tested postpartum had higher fasting and
3-hvaluesduringpregnancysuggeststhat
if a larger number of women had been
testedpostpartum,agreaterproportionof
the entire sample of GDM women would
have been found to be glucose intolerant
postpartum. Furthermore, 79% were
tested by FPG only. If a 75-g OGTT post-
partum test had been consistently admin-
istered, the prevalence of diagnosed
diabeteswouldmostlikelyhaveincreased
(20). Of the women in our sample who
had an OGTT postpartum with normal
FPG results, 8% had IGT or diabetes
based on their 2-h value.
Postpartum glucose testing
There has been signiﬁcant heterogeneity
across studies that have examined rates
andcorrelatesofpostpartumglucosetest-
ing after GDM with respect to calendar
years studied, time between delivery, and
postpartum testing population (hospital-
Table3—AdjustedORand95%CIforcharacteristicsassociatedwithpostpartumglucosetest
result categories among 5,508 women with a history of GDM who had postpartum glucose
testing, 1999–2006
IFG/IGT (n  893) vs.
normal (n  4,552)*
Presumptive diabetes (n  63)
vs. normal (n  4,552)*
Demographics
Age category, per 5 years 1.02 (0.95–1.10) 0.97 (0.75–1.25)
Race/ethnicity
Hispanic Referent Referent
Black 0.97 (0.73–1.30) 1.06 (0.46–2.48)
Asian/Paciﬁc Islander 1.24 (1.05–1.45) 1.46 (0.82–2.61)
Non-Hispanic white 0.79 (0.66–0.94) 0.45 (0.23–0.91)
Highest education
High school 1.09 (0.95–1.26) 0.82 (0.50–1.36)
High school graduate Referent Referent
High school graduate 0.89 (0.79–1.00) 0.91 (0.60–1.38)
Median household income
Lowest Referent Referent
Middle 1.09 (0.98–1.21) 0.91 (0.62–1.33)
Highest 0.88 (0.78–0.98) 0.74 (0.48–1.13)
Clinical
Parity
0 Referent Referent
1 0.97 (0.87–1.08) 1.04 (0.72–1.49)
2 1.09 (0.97–1.22) 0.99 (0.67–1.48)
Pharmacological GDM treatment
None Referent Referent
Insulin (/ oral agents) 1.57 (1.34–1.83) 3.30 (2.15–5.05)
Oral agents only 1.40 (1.09–1.81) 2.31 (1.22–4.36)
Infant birth weight
2,500 g 1.21 (0.99–1.48) 1.05 (0.51–2.16)
2,500–3,999 g Referent Referent
4,000 g 0.98 (0.82–1.16) 1.33 (0.78–2.25)
Health care
Timing of glucose testing
7 days to 6 weeks 0.74 (0.66–0.83) 0.42 (0.28–0.63)
6–12 weeks Referent Referent
12 weeks to 6 months 1.55 (1.33–1.80) 3.13 (2.13–4.61)
Temporal trend, per 1 year 0.94 (0.91–0.98) 1.03 (0.91–1.16)
*DataareadjustedOR(95%CI)fortheoutcomeofIFGand/orIGTandpresumptivediabetesversusnormal
test results. Final model includes 5,508 observations with complete data for each covariate (94% of the
sample with test results).
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aged care [15,16]) and the approach used
to identify women with GDM. The
present study included all women who
met the ADA criteria for GDM based on
theresultsfromthe100-gOGTTtestper-
formed during pregnancy, since ICD-9
codes alone was found to be an unreliable
meansofidentifyingwomenwithGDMin
our health plan database (2). Indeed,
while 16% of the women identiﬁed as
having GDM based on their prenatal
100-g OGTT results did not have a dis-
charge diagnosis of GDM, over one-third
(38.5%) of these women had postpartum
glucose testing. In spite of the differences
andconsistentwiththepresentstudy,ap-
proximatelyhalfofthewomenwithGDM
in the earlier studies underwent postpar-
tum testing (12,13,15–17).
Of the studies that examined GDM
pharmacological treatment in relation to
whether or not postpartum testing was
performed, two found a positive associa-
tion (14,16), one found a negative associ-
ation (13), and one found no association
(15). In the present study, we found that
while 50.3% of the women with no phar-
macotherapyand51.1%ofthewomenon
insulinweretested,only42.6%ofwomen
on oral agents had postpartum glucose
testing. Given that the women who took
oral agents only or insulin during their
GDM pregnancy and received postpar-
tum testing were 40 or 57% as likely to
have IFG/IGT and two to three times as
likely to have diabetes, respectively, as
women not treated with these medica-
tions,womenwhorequirepharmacother-
apy to control their blood glucose during
pregnancy should be tested in the post-
partum period.
Postpartum test results
In the three other studies reporting the
results of postpartum glucose testing
(12,13,16), the prevalence of diabetes
ranged from 2 to 8% compared with 1%
reported in the present study. Addition-
ally, the prevalence of IFG and/or IGT
ranged from 11 to 33%, compared with
16%inthepresentstudy.Inthetwostud-
ies (12,13) that used the same ADA crite-
ria to identify women as having GDM in
their clinical center as were used in the
presentstudy,72%ofthosetestedforglu-
cose intolerance in one of the centers had
an OGTT postpartum (13) compared
with only 21% in the present study. This
may have resulted in a higher proportion
of women identiﬁed as having impaired
glucose regulation in their population.
One study used the higher NDDG blood
glucose threshold (21) to identify women
with GDM and included tests conducted
from 6 weeks through 1 year postpartum
(16). Either or both of these factors may
have accounted for the higher prevalence
of impaired glucose regulation in their
population compared with our ﬁndings.
Limitations and strengths
We were unable to assess the occurrence
of postpartum glucose testing among the
15% of women with GDM who disen-
rolled from the health plan within 6
months after their deliveries. We could
not determine whether women were ad-
visedbyahealthcareprofessionaltohave
postpartum testing or whether the test
wasorderedbutnotcompleted,sincethis
information is not retained in the labora-
torydatabaseduringthestudyperiod.We
could also not determine if the patient re-
ceived a reminder to report for testing by
mail or telephone. Thus, missed tests
could be a result of lack of physician or-
ders or women not returning for postpar-
tum testing. Additionally, we were not
able to explore the associations between
obesity, postpartum testing, and ongoing
glucose abnormalities in the postpartum
period because maternal height and
weight were not available in clinical data-
bases or the California birth certiﬁcates
for the period of this study.
The strengths of this study include
the use of multiple clinical and adminis-
trative databases to identify and charac-
terize women with GDM, including
pharmacotherapy for GDM during preg-
nancy from a diverse insured cohort and
todeterminewhethermembersofthatco-
hort had been tested for glucose abnor-
malities postpartum. Because 95% (n 
11,187) of the women in the sample had
KPSC prescription drug coverage during
pregnancy, we were able to examine the
associations requiring anti-hyperglyce-
mic agents, postpartum testing, and test
results with a high level of accuracy. Our
sample included all women from 1999
through 2006 identiﬁed as having GDM
using a standard laboratory test (100-g
3-h OGTT) using ADA criteria to assess
the presence of GDM. Additionally, we
were able to identify those women found
to have IGT/IFG and those having a pro-
visionaldiagnosisofdiabetesusingthere-
sults of their 75-g OGTT and FPG tests
done during the postpartum period and
todescribethedemographic,clinical,and
healthserviceutilizationcharacteristicsof
those women.
Clinical implications
Testingforongoingglucosedysregulation
after a GDM-affected pregnancy may al-
low the opportunity for clinical interven-
tions to reduce the risk of developing
diabetes or treatment to reduce the risk of
diabetes-related complications among
women found to have diabetes (22). The
risk of pregnancy-related complications
among women with diabetes, a popula-
tion that is growing (2,23), may be re-
duced by optimal use of preconception
care (24). The ﬁndings from this and
other studies suggest that the rates of
postpartumglucosetestingafterGDMare
suboptimal. Rates of postpartum glucose
testing after GDM pregnancies may be in-
creased by incorporating alerts into elec-
tronicmedicalrecordssothatpostpartum
glucose testing orders are automatically
generated or physician-generated. Auto-
mated live or recorded telephone or e-
mail messages could also be used to
remind women to obtain testing after the
tests are ordered. Postpartum glucose
testing is an important ﬁrst step in at-
tempting to prevent both recurrence of
GDM and the development of nongesta-
tionaldiabetessubsequenttoapregnancy
complicated by GDM.
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